An instructive example of a long-latency adverse drug reaction - Sclerosing peritonitis due to practolol

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 11, 2007, Pages 1211-1216

  Mann, Ronald D ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Latent period; Oculomucocutaneous syndrome; Pharmacovigilance; Practolol; Sclerosing peritonitis; Yellow Card Scheme

Indexed keywords

PRACTOLOL;

ANGINA PECTORIS; ARTICLE; CONJUNCTIVITIS; CORNEA ULCER; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DRY EYE; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LACRIMATION DISORDER; LAPAROTOMY; LATENT PERIOD; MAJOR CLINICAL STUDY; PERICARDITIS; PHARMACOEPIDEMIOLOGY; PLEURA EFFUSION; PLEURAL FIBROSIS; PLEURISY; PRIORITY JOURNAL; PSORIASIS; SCLEROSING PERITONITIS; TREATMENT DURATION; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ADVERSE DRUG REACTION REPORTING SYSTEMS; GREAT BRITAIN; HUMANS; PERITONITIS; PRACTOLOL; PRODUCT SURVEILLANCE, POSTMARKETING; SCLEROSIS; TIME FACTORS;

EID: 36248981388     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1466     Document Type: Article

References (7)

1. Mann RD. A Ranked Presentation of the MHRA/CSM (Medicines & Health Care Regulatory Agency/Committee on Safety of Medicines) Drug Analysis Print (DAP) Data on Practolol. Pharmacoepidemiol Drug Saf 2005; 14: 705-710.
2. Nicholls JT. Adverse effects of practolol. Ann Clin Res 1976; 8: 229-231.
3. Nicholls JT. Post-marketing Surveillance of Adverse Reactions to New Medicines. Medico-Pharmaceutical Forum. Publication No. 7. 1978; 4-11.
4. Nicholls JT, Rutty DA. Sclerosing peritonitis with short-term propranolol therapy. Arch Intern Med 1980; 140: 1124-1125.
5. Committee on Safety of Medicines. Practolol (Eraldin) and Intestinal Obstruction. Current Problems No. 4. 1979; p. 1.
6. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. Br Med J 1998; 317: 119-120.
7. Heeley E, Riley J, Layton D, Wilton LV, Shakir SAW. Preacription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 356: 1872-1873.